If you take Eliquis, Jardiance, or a handful of other common medications, something historic happened to their prices this year — and it’s worth two minutes to understand.
For the first time, Medicare negotiated prices directly with drug manufacturers. Those negotiated prices took effect in January 2026 for ten medications: Eliquis, Xarelto, Jardiance, Farxiga, Januvia, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog.
The negotiated price is the starting point, but what YOU pay depends on your plan’s design — its tiers, deductible, and copays. Two people taking the same drug can see very different results. That’s why this is the year a plan review matters more than most.
Fifteen more drugs get negotiated prices in January 2027 — including Ozempic, Wegovy, and Rybelsus. If you take any of them, this fall’s enrollment period is the right time to look.
Make a list of your prescriptions, then have someone check how your plan prices each one for next year — “your plan is still the best fit” is a perfectly good outcome.
Plan-neutral — and “keep what you have” is always on the table.
Coverage reviews are local and built around you.